BCAR3 Polyclonal Antibody

Background:
breast cancer anti-estrogen resistance 3(BCAR3) Homo sapiens Breast tumors are initially dependent on estrogens for growth and progression and can be inhibited by anti-estrogens such as tamoxifen. However, breast cancers progress to become anti-estrogen resistant. Breast cancer anti-estrogen resistance gene 3 was identified in the search for genes involved in the development of estrogen resistance. The gene encodes a component of intracellular signal transduction that causes estrogen-independent proliferation in human breast cancer cells. The protein contains a putative src homology 2 (SH2) domain, a hall mark of cellular tyrosine kinase signaling molecules, and is partly homologous to the cell division cycle protein CDC48. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012],

Alternative Names:
BCAR3, NSP2, SH2D3B, Breast cancer anti-estrogen resistance protein 3, Novel SH2-containing protein 2, SH2 domain-containing protein 3B

Immunogen: The antiserum was produced against synthesized peptide derived from human BCAR3. AA range:761-810

Isotype: Rabbit

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration: 1 mg/ml

Observed band: 92

GeneID: BCAR3

Storage: -20°C/1 year

NOTE: For Research Use Only